Canada - inglese - Health Canada

jubilant generics limited - hydrochlorothiazide; olmesartan medoxomil - tablet - 25mg; 40mg - hydrochlorothiazide 25mg; olmesartan medoxomil 40mg - angiotensin ii receptor antagonists

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 20 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: hypromellose; purified water; hyprolose; lactose monohydrate; magnesium stearate; microcrystalline cellulose; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hypromellose; purified water; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 40 mg - olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure.  olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see dosage and administration (2) ] . lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure go

Australia - inglese - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; iron oxide red - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; hyprolose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; iron oxide red - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; iron oxide red - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Stati Uniti - inglese - NLM (National Library of Medicine)

solco healthcare us, llc - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 20 mg - olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see dosage and administration (2)] . lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals

Stati Uniti - inglese - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 20 mg - olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see dosage and administration (2)] . lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals

Stati Uniti - inglese - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 20 mg - olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see dosage and administration (2)] . lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals